Generic Neupro Availability

Neupro is a brand name of rotigotine, approved by the FDA in the following formulation(s):

NEUPRO (rotigotine - film, extended release;transdermal)

  • Manufacturer: UCB INC
    Approval date: May 9, 2007
    Strength(s): 2MG/24HR [RLD], 4MG/24HR, 6MG/24HR
  • Manufacturer: UCB INC
    Approval date: April 2, 2012
    Strength(s): 1MG/24HR, 3MG/24HR, 8MG/24HR

Has a generic version of Neupro been approved?

No. There is currently no therapeutically equivalent version of Neupro available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Neupro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Transdermal therapeutic systems having improved stability and their production
    Patent 6,699,498
    Issued: March 2, 2004
    Inventor(s): Walter; Müller
    Assignee(s): LTS Lohmann Therapie-Systeme AG
    This invention provides for, inter alia, a transdermal therapeutic system comprising at least one therapeutically active substance, which is oxidizable by hydroperoxides, wherein the amount of oxidative degradation of said active substances(s) and the corresponding formation of oxidative degradation products is reduced, which comprises one or more constituents of said transdermal therapeutic system being in contact with said active substance(s), wherein the sum of the peroxide number(s) (PON) of each of said constituents related to their percentage of the whole amount of said constituents as expressed by the formula ∑ i = 1 n ⁢   ⁢ ( N i · PON / 100 ) where N is the percentage content of the whole amount of said constituents in the TTS, n is the number of said constituents in the TTS, i is the running number PON is the peroxide number of each of the constituents, is not greater than 20.
    Patent expiration dates:
    • November 27, 2020
      ✓ 
      Drug product
  • Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof
    Patent 6,884,434
    Issued: April 26, 2005
    Inventor(s): Muller; Walter & Peck; James V.
    Assignee(s): LTS Lohmann Therapie-Systeme AG Aderis Pharmaceuticals, Inc.
    A transdermal therapeutic system, comprising a backing layer inert to the components of the matrix, a self-adhesive matrix layer containing (−)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol in an effective amount and a protective foil or sheet to be removed prior to use, is characterised by a matrix that is based on a non-aqueous, acrylate-based or silicone-based polymer adhesive system having a solubility of ≧5% (w/w) for (−)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]-amino]-1-naphthalenol, and said matrix is substantially free of inorganic silicate particulates.
    Patent expiration dates:
    • March 30, 2021
      ✓ 
      Drug product
  • Transdermal therapeutic system for treating Parkinsonism
    Patent 7,413,747
    Issued: August 19, 2008
    Inventor(s): Mueller; Walter & Peck; James V.
    Assignee(s): LTS Lohmann Therapie-Systeme AG Schwarz Pharma Limited
    A transdermal therapeutic system (TTS) comprises a silicone-based polymer adhesive system having distributed therein (−)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol free base in an amount of about 5% to 40% by weight. The adhesive system comprises a silicone adhesive and an additive having increased solubility for the active substance, in an amount effective to increase dissolving capacity of the matrix for the active substance.
    Patent expiration dates:
    • March 18, 2019
      ✓ 
      Drug product
  • Transdermal delivery system for the administration of rotigotine
    Patent 8,246,979
    Issued: August 21, 2012
    Inventor(s): Schacht; Dietrich Wilhelm & Hannay; Mike & Wolff; Hans-Michael
    Assignee(s): UCB Pharma GmbH
    An improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains rotigotine in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of rotigotine and is impermeable to the protonated form of rotigotine.
    Patent expiration dates:
    • September 1, 2027
      ✓ 
      Patent use: TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
      ✓ 
      Drug product
    • September 1, 2027
      ✓ 
      Patent use: TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM
      ✓ 
      Drug product
  • Transdermal delivery system
    Patent 8,246,980
    Issued: August 21, 2012
    Inventor(s): Schacht; Dietrich Wilhelm & Hannay; Mike & Wolff; Hans-Michael
    Assignee(s): UCB Pharma GmbH
    An improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains an amine-functional drug in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of the amine-functional drug and is impermeable to the protonated form of the amine-functional drug.
    Patent expiration dates:
    • November 27, 2025
      ✓ 
      Drug product
  • Transdermal delivery system for the administration of rotigotine
    Patent 8,617,591
    Issued: December 31, 2013
    Assignee(s): UCB Pharma GmbH
    An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use, characterized in that the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer (1) wherein rotigotine in its free base form has been incorporated, (2) which is saturated with rotigotine and contains said rotigotine as a multitude of microreservoirs within the matrix, (3) which is highly permeable for the free base of rotigotine, (4) which is impermeable for the protonated form of rotigotine, (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix. is provided. Said TDS provides for enhanced flux of rotigotine across the TDS/skin interface.
    Patent expiration dates:
    • July 22, 2023
      ✓ 
      Patent use: A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • April 2, 2015 - SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD)
    • April 2, 2015 - SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web1)